INMB Straddle Strategy
INMB (INmune Bio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB (INmune Bio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $38.8M, a beta of 1.05 versus the broader market, a 52-week range of 1.09-11.64, average daily share volume of 408K, a public-listing history dating back to 2019, approximately 13 full-time employees. These structural characteristics shape how INMB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.05 places INMB roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a straddle on INMB?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current INMB snapshot
As of May 15, 2026, spot at $1.57, ATM IV 127.70%, IV rank 19.53%, expected move 36.61%. The straddle on INMB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on INMB specifically: INMB IV at 127.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a INMB straddle, with a market-implied 1-standard-deviation move of approximately 36.61% (roughly $0.57 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INMB expiries trade a higher absolute premium for lower per-day decay. Position sizing on INMB should anchor to the underlying notional of $1.57 per share and to the trader's directional view on INMB stock.
INMB straddle setup
The INMB straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INMB near $1.57, the first option leg uses a $1.57 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INMB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INMB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.57 | N/A |
| Buy 1 | Put | $1.57 | N/A |
INMB straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
INMB straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on INMB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on INMB
Straddles on INMB are pure-volatility plays that profit from large moves in either direction; traders typically buy INMB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
INMB thesis for this straddle
The market-implied 1-standard-deviation range for INMB extends from approximately $1.00 on the downside to $2.14 on the upside. A INMB long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current INMB IV rank near 19.53% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on INMB at 127.70%. As a Healthcare name, INMB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INMB-specific events.
INMB straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INMB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INMB alongside the broader basket even when INMB-specific fundamentals are unchanged. Always rebuild the position from current INMB chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on INMB?
- A straddle on INMB is the straddle strategy applied to INMB (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With INMB stock trading near $1.57, the strikes shown on this page are snapped to the nearest listed INMB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are INMB straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the INMB straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 127.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a INMB straddle?
- The breakeven for the INMB straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INMB market-implied 1-standard-deviation expected move is approximately 36.61%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on INMB?
- Straddles on INMB are pure-volatility plays that profit from large moves in either direction; traders typically buy INMB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current INMB implied volatility affect this straddle?
- INMB ATM IV is at 127.70% with IV rank near 19.53%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.